| Document |
Document Title |
|
WO/2006/034641A1 |
The present invention discloses a process for producing Simvastatin and intermediate thereof. The present invention uses inexpensive and available reagent, its condition is mild, and it leaves out the protective and deprotective steps wh...
|
|
WO/2006/030892A1 |
The invention aims at providing a process for the production of NS-220 which is suitable for mass production on an industrial scale. The invention is constituted of (1) a process for the production of methyl cis-5-(4-chlorobutyl) -2-meth...
|
|
WO/2006/028972A2 |
Mercaptoamide compounds, represented by Formulas (IA), (IB), (IIA), and (IIB): or a pharmaceutically acceptable salt thereof, inhibit histone deacetylase enzyme and are useful for the treatment and/or prevention of various infections, ca...
|
|
WO/2006/021806A1 |
Compounds of formula (I) are useful in treatment of sleep disorders and other conditions mediated by 5-HT2A receptor activity.
|
|
WO/2006/022825A1 |
Various non-limiting embodiments disclosed herein related to photochromic materials comprising the reaction product of (a) at least one ring-opening cyclic monomer, and (b) a photochromic initiator. Other non-limiting embodiments related...
|
|
WO/2006/021805A1 |
Compounds of formula (I) are potent and selective antagonists of the human 5-HT2A receptor, and hence useful in treatment of a variety of adverse conditions of the CNS.
|
|
WO/2006/018855A1 |
Disclosed are novel compounds of general formula (I) where the symbols are as defined in the specification, their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them...
|
|
WO/2006/018524A1 |
The invention relates to a novel method for the synthesis of 2,5-dioxane-1,4-diones having formula (I), comprising the oxidation of the ketone function of a cyclic compound having formula (II), wherein R1, R2, R3 and R4 independently rep...
|
|
WO/2006/016708A1 |
Conventional many fungicidal compositions have had practical problems such that either a preventive effect or a curing effect is inadequate, the residual effect tends to be inadequate, or the controlling effect against plant diseases ten...
|
|
WO/2006/012227A2 |
The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor MR, and pharmaceutical compositions thereof. The compounds of the invention can be useful in the tr...
|
|
WO/2006/009134A1 |
A novel fungicide that exhibits a wide disease control spectrum against pathogenic fungi acting on various crops and helps resolve worsening resistant strain problems. There are provided diamine derivatives of the formula (1), a process ...
|
|
WO/2006/007634A1 |
The present invention relates to synthetic processes for the preparation of compounds bearing a dioxanyl moiety, in particular to compounds bearing a dioxanyl side chain attached to a mono- or polycyclic core moiety, more particularly a ...
|
|
WO/2006/007436A1 |
The present invention is directed to novel sulfamide and sulfamate derivatives, pharmaceutical compositions containing them and their use in the treatment of epilepsy and related disorders.
|
|
WO/2006/007435A1 |
The present invention is directed to novel sulfamide and sulfamate derivatives, pharmaceutical composlons containing them and their use in the treatment of epilepsy and related disorders.
|
|
WO/2006/003227A1 |
The invention relates to the synthesis of polyoxygenated nitrogen systems, comprising reactions between enamines of 1,3-dioxan-5-ones and nitroolefins. More specifically, the invention relates to the reaction between enamines having form...
|
|
WO/2006/002361A2 |
The present invention relates to inhibitors of 11-ß hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the ...
|
|
WO/2006/001318A1 |
Disclosed are a compound represented by the formula (I) below, prodrugs thereof, pharmaceutically acceptable salts of those and solvates of those. (I) (In the formula, R1 represents an ethyl which may be substituted by a halogen or an am...
|
|
WO/2005/123712A1 |
The invention relates to a method for the synthesis of compounds of general formula (1), (2), (3), (4). Said method consists of converting formulae (5) and (6) in the presence of formula (7), wherein R = substituted or unsubstituted alky...
|
|
WO/2005/123668A1 |
The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another ...
|
|
WO/2005/123089A2 |
Disclosed herein are carbonyl compounds of Formula (I) as described herein. Methods and compositions are disclosed for treating disease states including, but not limited to cancers, autoimmune diseases, tissue damage, central nervous sys...
|
|
WO/2005/123710A1 |
The invention relates to the derivatives of the benzoylcyclohexandiones of formula (I), wherein R1 and R2 represent different groups and Het represents a saturated heterocyclic group containing oxygen and carbon atoms, and to their use a...
|
|
WO/2005/121157A1 |
The present invention provides a compound represented by the formula (I): wherein ring A is void or a benzene ring optionally having substituent(s), R1 and R2 are each independently a phenyl group optionally having substituent(s), a cycl...
|
|
WO/2005/118566A1 |
A method for producing a 1,3-dioxolan-4,6-dione compound from a ketone compound and a malonic acid, the method comprising: precipitating a 1,3-dioxolan-4,6-dione compound as a crystal from a mixed solvent comprising a first organic solve...
|
|
WO/2005/118530A1 |
Disclosed are novel triketone compounds, a method for producing those, and an excellent herbicide containing those. Specifically disclosed are triketone compound represented by the formula (I) below or salts thereof. (I) [In the formula,...
|
|
WO/2005/115972A1 |
Compounds of formula I or pharmaceutically acceptable salts thereof: (I) wherein R1, R2, R3, R4, m and n are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are ...
|
|
WO/2005/116119A1 |
A compound represented by the formula (I) defined herein, and a process producing the compound represented by the formula (I) which comprises reacting the compound represented by the formula (III) defined herein with the compound represe...
|
|
WO/2005/113527A1 |
The present invention relates to novel tetrahydronaphthylpiperazines derivatives, that are compounds of the formula (I) wherein R1, R2 and R6 are as defined herein, X is CH2 or O, A is a group of the formula (G1, G2, G2a, G3, G4, G5 or G...
|
|
WO/2005/111134A2 |
An acetal-based composition useful as a nucleating, gelling, thickening or clarifying agent is disclosed. The composition may be synthesized or provided in many different forms, including multicarbon diacetals formed from carbohydrates. ...
|
|
WO/2005/108338A1 |
The present invention is directed to novel compounds according to formulae (I) wherein R1, R2, R3 and R4 are as defined herein. The invention also discloses methods of preparation, pharmaceutical compositions, and methods of disease trea...
|
|
WO/2005/108479A2 |
An acetal-based composition useful as a nucleating, gelling, thickening or clarifying agent is disclosed. The composition may be synthesized or provided in many different forms, including multicarbon diacetals formed from carbohydrates. ...
|
|
WO/2005/105775A1 |
For chemical recycling of polylactic acid or derivatives thereof or resin compositions containing them, there is provided a method of efficiently recovering or producing a lactide of high optical purity through depolymerization of polyla...
|
|
WO/2005/105744A1 |
This invention is directed to a compound of the formula (I) as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a method of treatment of a disorder or conditi...
|
|
WO/2005/105776A1 |
Compounds of the formula (I) or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein m, n, p, Ar, X, R1, R2, R3, R4, R5 and R6 are as defined herein as well as compositions comprising these compounds and uses of the s...
|
|
WO/2005/100345A1 |
The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions of compounds of Formula (A): wherein Ar, Y, R1 and ...
|
|
WO/2005/100308A1 |
The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions that include substituted biaryl-methanesulfinyl ace...
|
|
WO/2005/100301A1 |
The present invention relates to certain 2-aryloxyethyl glycine derivatives that exhibit activity as inhibitors of the glycine type-1 transporter, to pharmaceutical compositions containing them and to their use in the treatment of neurol...
|
|
WO/2005/097773A1 |
The present invention is related to carboxylic acids of Formula (I) and use thereof for the treatment and/or prevention of obesity and/or metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and...
|
|
WO/2005/094805A1 |
A medicine having prostaglandin D2 (PGD2) production inhibitory activity and having as an active ingredient a substance selected from compounds represented by the general formula (I): A-Y-B &lcub wherein A and B each independently repres...
|
|
WO/2005/095343A1 |
The invention relates to compounds of formula (I), Z-C(R1R2)-C(R3NH2)-C(R4R5)-X-N(R6R7), wherein Z, R1-7 and X have the meaning as cited in the description and the claims. Said compounds are useful as DPP-lV inhibitors. The invention als...
|
|
WO/2005/095378A2 |
The present invention is directed to carboxylic acid and ester moieties that are attached to a carbon chain that is between 2 and 24 carbons in length wherein, the chain contains at least one dioxanone ring system, said dioxanone being f...
|
|
WO/2005/087236A1 |
Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.
|
|
WO/2005/082842A1 |
A compound (II), compound (IV), compound (VI), and compound (VII); and processes for producing these. Also provided is a process for producing the compound (X) which comprises the steps of (II)→(IV)→(VI)→(VII)→(X).
|
|
WO/2005/083102A1 |
It is intended to provide a novel process for producing an optically active 1,4-benzodioxin-2-carboxylic acid derivative, which is usable as an intermediate in synthesizing an optically active drug, via biological conversion. Namely, a 6...
|
|
WO/2005/080322A1 |
A novel fluorene characterized by having a fluorene skeleton to which a functional group such as a guanidino group is attached via a carbonyl group, or its salt. This compound has such an advantage as showing a high affinity particularly...
|
|
WO/2005/079378A2 |
Synthetic methods and intermediates useful in the preparation of lactone containing compounds such as discodermolide and compounds which mimic the chemical or biological activity of discodermolide are provided.
|
|
WO/2005/077943A2 |
The present invention discloses novel compounds of formula (I) and their pharmaceutically useful compositions as modulators of PPAR ligands
|
|
WO/2005/077882A1 |
A chain or cyclic oligolactate having an aminoethyl, hydroxyethyl, or carboxymethyl group in a side chain. A chain oligolactate having an aminoethyl, hydroxyethyl, or carboxymethyl group in a side chain is synthesized first. This chain o...
|
|
WO/2005/077943A1 |
The present invention discloses novel compounds of formula (I) and their pharmaceutically useful compositions as modulators of PPAR ligands
|
|
WO/2005/077868A2 |
The invention relates to congeneric, halogenated, fluorinated, aromatic compounds (I), (II), (IIIa) or (IIIb), (IV), (V), (VI) or (VII), in which A and B represent phenyl groups, L represents an oxygen atom, sulphur atom or an alkene gro...
|
|
WO/2005/075401A1 |
The invention relates to a method for producing 2,5-dimethylphenyl acetic acid by reacting p-xylol with chloroacetyl chloride to form 2-chloro-1-(2,5-dimethylphenyl) ethanone, which reacts with the compound of formula (II) to form the co...
|
